A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

Sponsor and Collaborators     
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health Clinical Center (CC)

Contact    
Barbara Weinstein, R.N.     
(301) 594-4180     
weinsbar@nhlbi.nih.gov

Investigator
National Heart, Lung, and Blood Institute (NHLBI)

ClinicalTrials.gov Identifier
NCT00217594

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs